FDA Must Address Lannett's Lies On Cocaine Drug, Suit Says
Law360 (November 13, 2020, 6:22 PM EST) -- A small drugmaker is accusing the U.S. Food and Drug Administration in Maryland federal court of disregarding false information in a Lannett Co. application for a cocaine-based numbing agent, the latest chapter in the company's efforts to protect its cocaine anesthetic that has been on the market for years.
The FDA illegally failed to take steps to withdraw its approval of Lannett's new drug application for Numbrino, a cocaine-based anesthetic, after Genus Lifesciences Inc. told the regulator that Lannett lied about where it was manufacturing the product, Pennsylvania-based Genus says in a lawsuit filed Thursday.
"Genus brought these material, untrue statements...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!